Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2025-05-13 00:00:00 ET · period of report 2025-05-09 · accession 0002001011-25-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-05-13 | 2025-05-09 | LGND | Espinoza Octavio | CFO | P - Purchase | $104.06 | +1,500 | 27.9K | +6% | +$156.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-09 | P | A | 1,000 | $103.89 | 27,432 | D | — | — | (F2) The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP). |
| 2 | Common | Common Stock | 2025-05-09 | P | A | 500 | $104.40 | 27,932 | D | — | — | (F2) The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP). |